Actively Recruiting
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Led by University of Chicago · Updated on 2026-03-04
1200
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how to collect and use DNA samples from patients who receive regular healthcare at the University of Chicago. The study aims to identify genetic differences that could influence the risk of side effects or benefits from certain medications. The project focuses on patients with various conditions including heart diseases, autoimmune disorders, inflammatory diseases, blood coagulation disorders, hepatitis C, and non-metastatic cancer. Participants in this observational study include adults receiving routine outpatient care, particularly those taking prescription medications or likely to need them soon. DNA samples will be tested for pharmacogenomic markers, and the results will be shared with the patients' treating physicians. The study tracks whether this genetic information affects medication decisions in usual healthcare. Participants provide DNA samples and their healthcare is monitored over time to see how pharmacogenomic data is used. The main outcome measured is how feasible it is to include pharmacogenomic testing in routine care over five years. Researchers also observe if having this genetic information changes drug choices. Patients' usual care continues throughout the study, which lasts several years.
CONDITIONS
Brief Title
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Receiving ongoing, outpatient care at the University of Chicago Medical Center under a participating physician
- Life expectancy of at least 3 years
- Must be 18 years or older
- Taking between 1 and 6 prescription medications at enrollment OR be 65 years or older OR expected to need prescription medication within the next 5 years
- Patients with specialized cardiology care, inflammatory bowel diseases, systemic autoimmune or inflammatory diseases, long-term oral anticoagulation, hepatitis C, or non-metastatic cancer are especially encouraged to enroll
You will not qualify if you...
- Having acute or chronic disease expected to result in death within 3 years
- Having had or being considered for liver or kidney transplantation
- Inability to understand and give informed consent to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants who undergo routine care are observed to study the incorporation of pharmacogenomic testing into medical care and its impact on drug decision making.
Regular visits as part of routine outpatient care
Trial Site Locations
Total: 1 location
1
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
1
1200 Patients Project Study Team
C
Cancer Clinical Trials Office
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here